Buy & Sell Taskus Inc (TASK) – Taskus Inc Price Today
Aura AI Summary
Key Stats
- $512.84MMarket Cap
- TechnologySector
- -51.82%3M Drawdown
- $908.54MEnterprise Value
- -Dividend Yield
- 56% Buy | 44% SellTrading Activity
- 26 daysTypical Hold Time
Taskus Inc (TASK) is currently valued at a market capitalization of $512.84M, with an enterprise value of $908.54M. Over the past 52 weeks, Taskus Inc has traded between a low of $5.49 and a high of $18.21, highlighting its annual price range. Over the past three months, Taskus Inc has recorded a drawdown of -51.82%, reflecting recent price volatility. On average, investors hold Taskus Inc for approximately 26 days, indicating typical investor behavior on the platform.
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Most Recent News
Vuzix showcases advanced waveguide smart glasses for defense at SOF Week 2026 in Florida
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...

Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...

ANKTIVA combo shows higher response rates and fewer side effects vs rival bladder cancer therapies
ImmunityBio presented data showing its ANKTIVA plus BCG treatment outperformed two FDA-approved bladder cancer therapies, Adstiladrin and INLEXZO. The ANKTIVA combo achieved a 69.7% complete response rate versus 53.4% for Adstiladrin, with a longer m...
